July 17th, 2022 (Earnings Report)Dear Reader,Our scanners just identified several healthtech stocks that are expected to release earnings starting today, July 18th.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Artelo Biosciences
Symbol: ARTL
Recent Price: $0.34
Average Analyst Price Target: $4.00 (1076.47%)
Market Cap: $14.38M
Last Year's EPS: -$0.1
Consensus EPS Forecast: -$0.06
Expected Earnings Date: Jul 18 2022
Recent Analyst Action: Michael Higgins, analyst at Ladenburg Thalmann & Co., reiterates coverage on Artelo Biosciences (ARTL) in the Healthcare sector with a Buy rating and a price target of $ 4 (2 weeks ago).
TipRanks.com also reports that Artelo Biosciences currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $4.00 . The target pricing ranges from a high forecast of $4.00 down to a low forecast of $4.00. Artelo Biosciences (ARTL)’s last closing price was $$0.34 which would put the average price target at 1076.47% upside.Here are 3rd party ratings for ARTL:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 29% (73 out of 251)
--------------------------------------------------------------------------
Johnson & Johnson
Symbol: JNJ
Recent Price: $178.23
Average Analyst Price Target: $192.50 (8.01%)
Market Cap: $468.99B
Last Year's EPS: $2.48
Consensus EPS Forecast: $2.54
Expected Earnings Date: Jul 18 2022
Recent Analyst Action: Larry Biegelsen, analyst at Wells Fargo, reiterates coverage on Johnson & Johnson (JNJ) in the Healthcare sector with a Buy rating and a price target of $ 195 (4 days ago).
TipRanks.com also reports that Johnson & Johnson currently has 10 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $192.50 . The target pricing ranges from a high forecast of $205.00 down to a low forecast of $174.00. Johnson & Johnson (JNJ)’s last closing price was $178.23 which would put the average price target at 8.01% upside.Here are 3rd party ratings for JNJ:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 38% (96 out of 251)
--------------------------------------------------------------------------
Biotage AB
Symbol: BITGF
Recent Price: $17
Average Analyst Price Target: $23.78 (39.88%)
Market Cap: $1.28B
Last Year's EPS: $0.07
Consensus EPS Forecast: $0.08
Expected Earnings Date: Jul 18 2022
Recent Analyst Action: Odysseas Manesiotis, analyst at Berenberg Bank, reiterates coverage on Biotage AB (BITGF) in the Healthcare sector with a Buy rating and a price target of $ 25.07 (1 week ago).
TipRanks.com also reports that Biotage AB currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $23.78 . The target pricing ranges from a high forecast of $25.07 down to a low forecast of $22.50. Biotage AB (BITGF)’s last closing price was $17 which would put the average price target at 39.88% upside.Here are 3rd party ratings for BITGF:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: n/a, n/a
--------------------------------------------------------------------------
Abbott Labs
Symbol: ABT
Recent Price: $108.82
Average Analyst Price Target: $128.08 (17.70%)
Market Cap: $190.54B
Last Year's EPS: $1.17
Consensus EPS Forecast: $1.13
Expected Earnings Date: Jul 19 2022
Recent Analyst Action: Jayson Bedford, analyst at Raymond James, reiterates coverage on Abbott Labs (ABT) in the Healthcare sector with a Buy rating and a price target of $ 117 (2 days ago).
TipRanks.com also reports that Abbott Labs currently has 12 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $128.08 . The target pricing ranges from a high forecast of $143.00 down to a low forecast of $95.00. Abbott Labs (ABT)’s last closing price was $108.82 which would put the average price target at 17.70% upside.Here are 3rd party ratings for ABT:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 49% (127 out of 251)
--------------------------------------------------------------------------
Biogen
Symbol: BIIB
Recent Price: $$217.01
Average Analyst Price Target: $245.95 (13.34%)
Market Cap: $$31.78B
Last Year's EPS: $5.68
Consensus EPS Forecast: $4.14
Expected Earnings Date: Jul 19 2022
Recent Analyst Action: Brian Skorney, analyst at Robert W. Baird, reiterates coverage on Biogen (BIIB) in the Healthcare sector with a Hold rating and a price target of $ 224 (5 days ago).
TipRanks.com also reports that Biogen currently has 19 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $245.95 . The target pricing ranges from a high forecast of $320.00 down to a low forecast of $185.00. Biogen (BIIB)’s last closing price was $217.01 which would put the average price target at 13.34% upside.Here are 3rd party ratings for BIIB:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 29% (73 out of 251)
--------------------------------------------------------------------------
Elevance Health
Symbol: ELV
Recent Price: $488.92
Average Analyst Price Target: $568.40 (16.26%)
Market Cap: $117.87B
Last Year's EPS: $7.03
Consensus EPS Forecast: $7.75
Expected Earnings Date: Jul 19 2022
Recent Analyst Action: Ricky Goldwasser, analyst at Morgan Stanley, reiterates coverage on Elevance Health (ELV) in the Healthcare sector with a Hold rating and a price target of $ 533 (3 weeks ago).
TipRanks.com also reports that Elevance Health currently has 20 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $568.40 . The target pricing ranges from a high forecast of $642.00 down to a low forecast of $335.00. Elevance Health (ELV)’s last closing price was $488.92 which would put the average price target at 16.26% upside.Here are 3rd party ratings for ELV:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 32% (80 out of 251)
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com
